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http:WHAT THIS PAPER ADDS
In literature, large series evaluating the mid-term and or long-term results of endovascular treatment for aortic
arch branch origin (AABO) obstruction are scarce. This study evaluated the mid-term and long-term results of
AABO to show that endovascular treatment of arch branch origin obstruction is a procedure of acceptable safety
with good mid-term results.Objectives: Endovascular treatment of atherosclerotic obstruction of aortic arch branch origins (AABO) has
largely replaced open surgery, but long-term outcome data are lacking. This study evaluated mid-term and long-
term results of these procedures.
Design: Retrospective cohort study.
Materials and methods: Patients underwent endovascular treatment for symptomatic atherosclerotic stenosis of
AABO between 1995 and 2012. Technical success was deﬁned as uncomplicated revascularization and residual
stenosis 30%. The primary end point was freedom from restenosis 50% on Duplex ultrasonography or
magnetic resonance angiography. Secondary end points were freedom from target lesion revascularization or
recurrent symptoms.
Results: 144 lesions were treated in 114 patients (75 female; mean age 66.3 years), by percutaneous transluminal
angioplasty (PTA) in 20 patients and PTA and stent in 117 patients (brachiocephalic artery [BCA] 9/54; left
common carotid artery [LCCA] 0/7; left subclavian artery [LSA] 11/56). The lesion could not be passed in four
patients, and in three patients the intervention was terminated before angioplasty. The 30-day technical success
was 94.4%, without deaths or strokes. Mean follow-up was 52.0 months (range 2e163 months). Restenosis-free
survival was 95.6%, 92.9%, 87.6%, and 83.2% at 12, 24, 48, and 60 months, respectively. Log-rank test showed no
signiﬁcant difference between PTA only and PTA with additional stent placement at any point (p ¼ .375), nor
between BCA (n ¼ 51), LCCA (n ¼ 6), or LSA (n ¼ 57). During follow-up, 27 patients (23.7%) became symptomatic
(15 BCA, 1 LCCA, and 11 LSA); 19 patients with a restenosis of the target lesion (mean 56.7 months). Symptom-
free survival was 94.7%, 92.0%, 82.3%, and 77.9% at 12, 24, 48, and 60 months, respectively.
Conclusion: Endovascular treatment of aortic arch branch origin obstruction is safe and efﬁcacious in
experienced hands and can be considered as the preferred treatment, with good mid-term durability. Recurrent
symptomatic lesions can be treated safely by renewed endovascular means.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In the general population, the incidence of signiﬁcant ste-
nosis or occlusion at an aortic arch branch origin (AABO)
ranges from 0.5% to 6.4%, with higher occurrence in the
brachiocephalic artery (BCA) and left subclavian artery (LSA)
compared with the left common carotid artery (LCCA).1,2
Until 30 years ago, AABO steno-occlusive disease could be
treated only with open surgery.3,4 Despite high long-term
Table 1. Summary of patient, lesion, and procedure characteristics.
Patient characteristics
Total number of patients 114 (100%)
Average age, years 66.3 (range 42e77)
Female 75 (65.8%)
Comorbidity
Smoker 16 (14.0%)
Hypertension 34 (29.8%)
Hypercholesterolemia 29 (25.4%)
Diabetes mellitus type 2 13 (11.4%)
Preprocedural symptoms Total interventions: 144
TIA 12 (8.3%)
Stroke 1 (0.7%)
Cerebrovascular insufﬁciency 14 (9.7%)
Amaurosis fugax 35 (24.3%)
Upper limp claudication 52 (36.1%)
Dizziness 26 (18.1%)
Subclavian steal syndrome 5 (3.5%)
Lesion characteristics Total interventions: 144
<50% stenosis 0 (0.0%)
14 M.A.J. van de Weijer et al.patency, open surgery has been associated with substantial
morbidity and mortality rates.3,4
Nowadays, PTA, with or without stenting, is considered
feasible and safe and is accepted by most specialists as the
ﬁrst line of treatment for AABO lesions.3,4 However, re-
ported adverse effects are signiﬁcant residual stenosis, a
high rate of restenosis, and dissection, resulting in limited
durability and, ultimately, the need for additional vascular
interventions.5
Published reports on endovascular treatment of athero-
sclerotic stenosis or occlusion of the AABO are relatively
scarce, with a limited numbers of cases, including only four
reports of more than 50 procedures.2,6e8 Furthermore,
these studies are mostly limited to initial success or short-
term outcome only. The aim of the present cohort study
was to evaluate the mid-term and long-term beneﬁt of
endovascular treatment of clinically signiﬁcant stenosis or
occlusion of the AABO.50e70% stenosis 71 (49.3%)
>70% stenosis 68 (47.2%)
Occlusion 5 (3.5%)
Procedure characteristics Total interventions: 144
Technical success 136 (94.4%)
PTA alone 20 (13.9%)
PTA and stent placement
Residual stenosis >30%
117 (81.2%)
1 (0.7%)
Values are given as n (%), unless otherwise stated.
PTA ¼ percutaneous transluminal angioplasty; TIA ¼ transient
ischemic attack.MATERIALS AND METHODS
Patients and lesions
The study included all patients with symptomatic athero-
sclerotic lesions of the AABO who received primary endo-
vascular therapy in two large tertiary referral vascular
centers in the Netherlands (St. Antonius Hospital, Nieuwe-
gein: 64 patients, 77 interventions, and University Medical
Center Utrecht: 50 patients, 67 interventions) between
September 1995 and March 2012. The institutional review
boards of both hospitals approved this retrospective case
cohort analysis.
The initial diagnosis of AABO stenosis or occlusion was
based on clinical symptoms and a physical examination.
Additional imaging, including duplex ultrasonography (DUS),
magnetic resonance arteriography (MRA), and/or computed
tomography arteriography (CTA), revealed a 50% stenosis
or occlusion. The diagnosis of subclavian steal syndrome
was based on ipsilateral effort-related fatigue, a blood
pressure gradient between the upper extremities, and DUS
documented retrograde ﬂow in the vertebral artery (VA)
caused by signiﬁcant stenosis of the subclavian artery.
Inclusion criteria for intervention and the present analysis
were symptomatic primary stenosis 50% or occlusion at
the AABO. All patients and indications for revascularization
were discussed in multidisciplinary panels consisting of
interventional radiologists, vascular surgeons, and vascular
neurologists. Baseline patient characteristics are summa-
rized in Table 1.Preinterventional and postinterventional imaging
The preprocedural examination consisted of color-coded
DUS, MRA, or CTA of the AABO. At least two imaging
studies were performed in 112 of 114 patients to conﬁrm
the diagnosis and prepare for an optimal intervention
strategy. Also, two imaging studies were performed in all
patients receiving endovascular reintervention or re-
reintervention. Origin obstruction was deﬁned as anocclusion or stenosis of 50% at the transition of the aortic
arch to the supra-aortic branch arteries.
A DUS-based peak systolic velocity (PSV) measurement of
more than 125 cm/s was the applied threshold for >50%
stenosis and a PSV value of 210 cm/s was the threshold for
>70% stenosis. Postprocedural imaging at follow-up was
performed with DUS. Additional CTA imaging was per-
formed in the event of renewed symptoms and suspicion of
(in-stent) restenosis.Endovascular procedure
All procedures (Fig. 1) were performed in the angiography
suite under local anesthesia. Initial arterial access was
gained through the common femoral artery with an 8F
introduction sheath (Cook Medical Inc., Bloomington, IN,
USA). If necessary, a brachial approach was gained through
a 4F or 5F introducer sheath.
Angle-tip or straight-tip Terumo guidewires (Terumo Med-
ical, Tokyo, Japan) with a 0.032-inch or 0.035-inch diameter
were used to pass the lesion in the supra-aortic arteries. In
occlusions, recanalization froma femoral approachwas always
attempted ﬁrst. If the lesion could not be crossed, despite the
use of selective catheters (e.g. super torque; Cordis, Johnson&
Johnson, Fremont, CA, USA) with high support, a combined
brachial and femoral approach was used.
When the lesion was passed, balloon angioplasty was
performed as a primary angioplasty intervention or as
Figure 1. Endovascular treatment of origin stenosis of the brachiocephalic trunk. (A) Digital subtraction angiography of aortic arch in a 52-
year-old male with vertebrobasilar insufﬁciency, showing hemodynamically signiﬁcant stenosis at the origin of the brachiocephalic trunk.
(B) After passing the stenosis a balloon expandable stent (Palmaz Genesis 8  24, Cordis Johnson & Johnson, Fremont, CA, USA) is placed.
(C) Inﬂation of the balloon. (D) Control angiography obtained after stent placement.
Atherosclerotic Aortic Arch Branch Origin Obstruction 15predilatation before stent placement. PTA with additional
stent placement was the primary choice of intervention;
however, the decision to use PTA alone or to use an addi-
tional stent was determined by the type of lesion (e.g.
extent of lesion, residual stenosis, translesion pressure) and
rested with the interventionalist performing the procedure.
Different types of stent were used according to personal
preference of the interventional radiologist (Table 2).
Technical success was deﬁned as a residual diameter
reduction of less than 30% on intraprocedural control
angiography. Initial clinical success was deﬁned as relief or
substantial reduction of the preprocedural symptoms, as
listed in Table 1.End points
The primary end point was deﬁned as freedom from reoc-
clusion or restenosis, deﬁned as a lumen reduction of 50%
of the target lesion established with DUS.
Secondary end points were deﬁned as freedom from
target lesion revascularization (TLR) during follow-up,
freedom from adverse cardiovascular events (i.e. compos-
ite of death, stroke, myocardial infarction, or residual arm
claudication by subclavian steal syndrome), and any other
revascularization procedure for aortic arch branch origin
stenosis in another target vessel.Table 2. Stents used by initial intervention.
Stents used No.
Palmaz Genesis 54
Jomed 19
Express 6
Wall 4
Corinthian 2
Life 2
Unknown 30
Total stent placements 117
Palmaz Genesis: Cordis Johnson & Johnson, Fremont, CA, USA.
Jomed: Jomed International AB, Helsingborg, Sweden. Express:
Boston Scientiﬁc Corporation, Natrick, MA, USA. Wall: Boston
Scientiﬁc Corporation, Natrick, MA, USA. Corinthian: Cordis
Johnson & Johnson, Fremont, CA, USA. Life: Bard Peripheral
Vascular, Tempe AZ, USA.Primary patency was deﬁned as freedom from reinter-
vention of the target lesion during follow-up. Assisted pri-
mary patency was deﬁned as patency of the target lesion
after endovascular reintervention in case of symptomatic
restenosis but without occlusion at any time.Follow-up
Postoperative clinical evaluation and DUS follow-up was
performed at 3 and 12 months after the intervention and
annually thereafter. Restenosis was deﬁned as recurrent
lumen reduction 50% deﬁned by the same DUS threshold
criteria as those applied for preintervention imaging.Statistical analysis
Statistical inferences were made using KaplaneMeier tests
and log-rank tests using IBM SPSS Statistics 20.0 software
(IBM Corp, Armonk, NY, USA). A p value of <.05 was
considered statistically signiﬁcant. KaplaneMeier analysis
was used to calculate the secondary end point rates. Log-
rank tests were used to calculate the difference between
secondary end points of PTA only and PTA with additional
stent placement. The log-rank test was also used to calcu-
late differences between secondary end points among the
BCA, LCCA, and LSA.RESULTS
Patient and lesion characteristics
Between September 1995 and March 2012, 114 patients
(75 female; mean age 66.3 years, range 42e77 years) with
signiﬁcant obstruction of the AABO underwent 144
endovascular interventions (BCA in 67, LCCA in 7, LSA in
70). Preprocedural symptoms are listed in Table 1 and
consisted of cerebrovascular insufﬁciency (e.g. transient
ischemic attack, vertebrobasilar insufﬁciency, stroke,
amaurosis fugax, subclavian steal syndrome) or symptoms
related to upper limb ischemia. At baseline, all lesions
were primary lesions. Preintervention imaging revealed
ﬁve occlusions (3.5%) and 139 signiﬁcant stenoses >50%
(Table 1).
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Balloon angioplasty only was performed in 20 lesions
(13.9%), and angioplastywith additional stent placementwas
performed in 117 (81.2%). The lesion could not be passed in
four patients, and in three patients the intervention was
terminated before angioplasty because of minor complica-
tions. The stents used are listed in Table 2. In 124 in-
terventions (86.1%), successful access was gained from the
femoral artery approach, whereas in 12 interventions the
lesion had to be passed through additional brachial artery
access after initial femoral attempts had failed. Brachial ar-
tery access was needed because of subtotal ostial stenosis
(n ¼ 10), and in two interventions because of substantial
concomitant aortic arch artery pathology.
In another four lesions (two occlusions and two origin
stenosis >70%), the lesion could not be passed by femoral
or brachial approach. In one further case, a >30% residual
stenosis remained after multiple inﬂations of the PTA
balloon. In three patients minor complications led to
termination of the intervention before angioplasty; no PTA
was performed in one case because the interventionalist
observed plaque extension to the origin of the VA with
feared plaque protrusion into the VA origin; in another
patient, a perforation with extravasation of the BCA
occurred after cannulation, without further sequelae; and
the last case was discontinued because of atrial ﬁbrillation,
leading to a technical success of 136/144 (94.4%).Figure 2. (A) KaplaneMeier curve shows primary patency, symptom-fr
shows primary patency of ipsilateral and contralateral restenosis. (C) P
PTA intervention, with or without stent placement, for treatment of oOutcome at 30 days
Signiﬁcant reduction or complete relief of symptoms
occurred in 103 of 114 patients, giving a clinical success rate
of 90.4%. In four interventions the lesion could not be
passed using a femoral or brachial approach, and in another
three patients the procedure was terminated before PTA
because of minor complications. These three patients were
treated conservatively. Four patients with a technically
successful procedure had no signiﬁcant relief or reduction
of preprocedural symptoms (dizziness in three; arm clau-
dication in one patient).Follow-up >30 days
Follow-up examination was performed up to 13.5 years
after revascularization, with a mean follow-up time of 52.0
months (range 2e163 months). Of the 114 patients, 12 died
at a mean of 28.2 months post procedure (range 6e87
months) of noncardiovascular causes, and one patient
declined further follow-up after 24 months. The overall
primary patency was 95.6% at 12 months, 92.9% at 24
months, 87.6% at 48 months, and 83.2% at 60 months. The
symptom-free survival was 94.7%, 92.0%, 82.3%, and
77.9%, respectively (Fig. 2A). The primary assisted patency
was 100%, 99.1%, 98.2%, and 97.3%, respectively (Fig. 2A).
During follow-up, 27 endovascular repeat interventions
were performed for AABO restenosis of the BCA (15/67ee survival, and assisted primary patency. (B) KaplaneMeier curve
atency: PTA only versus PTA with additional stent placement. (D)
rigin stenosis of the BCA, LCCA, or LSA, respectively.
Atherosclerotic Aortic Arch Branch Origin Obstruction 17[22.4%]), LCCA (1/7 [14.3%]), and LSA (11/70 [15.7%]). Of
the 27 endovascular repeat interventions, 19 were per-
formed for recurrent stenosis at the location of the initial
target lesion (repeat TLR). As a secondary end point, eight
interventions were performed for severe stenosis in a
different artery from the original lesion (Fig. 3, Table 3).
These 27 procedures were performed in patients with
symptomatic presentation. In nine patients, an asymptom-
atic restenosis of the original target vessel was detected,
which was treated conservatively in all cases. All repeat
intervention procedures were technically successful.
Overall, 23 of the 27 endovascular reinterventions
(85.2%) were PTA with additional stent placement, whereas
the initial intervention in the other four was PTA only. Three
patients needed more than one reintervention during
follow-up (Fig. 4). The primary patency of the repeat TLR
was 95.6% at 12 months, 94.7% at 24 months, 92.0% at 48
months, and 89.4% at 60 months. The primary patency of
the interventions to treat other AABO arteries was 100%,
98.2%, 95.6%, and 93.8%, respectively (Fig. 2B).
Fig. 2C shows the survival function for PTA-only treat-
ment and the survival function for PTA treatment with
additional stent placement. The restenosis-free survival for
PTA with additional stent placement was 97.0%, 95.0%,
90.1%, and 85.1%, respectively. The restenosis-free survival
for PTA only was 84.6% at 12 months, 76.9% at 24 months,
and 69.2% at 48 and 60 months. There was no signiﬁcant
difference in short-term outcome between PTA with
stenting and PTA alone, and no signiﬁcant difference be-
tween restenosis-free survival of PTA treatment with or
without stent placement (p ¼ .375).Figure 3. Repeat and alternative interventions.
Table 3. Follow-up >30 days.
Follow-up examination, years 13.5
Follow-up mean (range), months 52.0 (2e163)
Total patients, n 114
Death during follow-up, n 12
Refused follow-up, n 1
Total initial interventions, n 114
Total repeat interventions, n 27
Total repeaterepeat interventions, n 3
Total interventions, n 144
Symptomatic during follow-up, n 27
Recurrent stenosis, n 19
Alternative stenosis, n 8The restenosis-free survival of endovascular PTA treat-
ment, with or without additional stent placement, split for
BCA, LCCA, and LSA is projected in Fig. 2D.
Restenosis-free survival for BCA at 12, 24, 48, and 60
months was 94.1%, 90.2%, 84.3%, and 82.4%, respectively,
was 83.3% for the LCCA, and was 98.2%, 96.5%, 91.2% and
84.2%, respectively, for the LSA. The overall restenosis-free
survival was 95.6%, 92.9%, 87.6% and 83.2%, respectively.
The log-rank test between the BCA, LCCA, and LSA showed
no signiﬁcant difference (p ¼ .473).DISCUSSION
In general, there are three methods for treating lesions of
the AABO: (1) a transthoracic approach, (2) an extra-
thoracic approach, and (3) an endovascular approach.9,10
The transthoracic approach is associated with signiﬁcant
mortality rates (4.3e8%)10; however, despite the signiﬁcant
mortality rate and discomfort, the transthoracic approach
has high long-term patency rates.3,4,9 The extra-thoracic
approach seems to have similar patency rates (96% and
88e91% after 1 and 5 years, respectively) with a lower
operative mortality rate (0.5e2%).9,10
In the present series on endovascular treatment, no
periprocedural death occurred and patency rates were
95.6% at 1 year to 83.2% at 5 years, similar to the patency
rates of the other two approaches except for the long-term
patency. This suggests that the endovascular approach can
be safely applied as the ﬁrst treatment option.
Moreover, it was found that endovascular treatment of
AABO obstruction is safe and efﬁcacious in the great ma-
jority of treated patients and can be considered as the
preferred treatment. The durability of this approach seems
acceptable in the mid-term and may be superior with pri-
mary stenting. Recurrent symptomatic lesions can be safely
treated by endovascular means.
The initial technical success rate in the present study was
94.4%, and the clinical success rate was more than 90% on
an intention-to-treat basis. These observations are in line
with previous reports; for per protocol PTA with stenting7 as
well as for standardized PTA alone.8 Of the 114 patients,
four had no signiﬁcant relief of preprocedural symptoms
and four lesions could not be passed. Three patients had
minor complications according to the Society of Interven-
tional Radiology standards. There were no deaths or per-
manent neurologic complications.
Large series evaluating the mid-term and/or long-term
results of endovascular treatment for AABO obstruction
are scarce (Table 4). One study7 described the results of
endovascular treatment of the supra-aortic arteries in 83
patients with a follow-up of almost 5 years. All patients
were treated with angioplasty with additional stent place-
ment. This study showed a primary success rate of 94.3%
and a primary patency rate of 85.0% at 35 months. The
study found with the most interventions reported the re-
sults of 131 cases with a mean follow-up of 60 months.8 All
procedures were performed without additional stent
placement. The primary success rate was 93.0%, and the
Figure 4. Flowchart of treatment in terms of interventions and number of patients at risk.
18 M.A.J. van de Weijer et al.primary patency rate of 96.3% at 60 months. These results
for PTA alone should be considered as outstanding and
unique.
The ﬁndings in this comparatively large series suggest
that additional primary stent placement after PTA inter-
vention may provide higher primary and secondary patency
rates, although no statistical difference could be detected.
However, this result is potentially limited by the possibilityof bias regarding the nonrandomized preprocedural deci-
sion on the endovascular approach, using PTA only versus
PTA with stent. The present study revealed that in 10% of all
interventions, access was gained through the brachial artery
after initial femoral attempts. The brachial approach was
initiated because the lesion could not be passed by the
femoral approach because of the high degree of stenosis or
to aortic arch pathology. This may be of relevance when
Table 4. Literature of endovascular treatment of origin stenoses of supra-aortic arteries.
Author (ﬁrst author) Year Total Int. Stents, % Interventions Symptomatic
patients, %
PSR SR (SR/months) FU (mean
months)
Current study 2014 144 81.3 BCA n ¼ 67 100 94.4% 95.6%/12 52.0
LSA n ¼ 70 92.9%/24
CCA n ¼ 7 83.2%/60
Muller-Hulsbeck6 2007 55 40.0 BCA n ¼ 7 100 100 90.6%/20 22.00
LSA n ¼ 36
CCA n ¼ 6
Axillary n ¼ 5
Peterson11 2006 20 100 BCA n ¼ 8 80 100 100%/1 12
LSA n ¼ 3
CCA n ¼ 9
Przewlocki2 2005 76 86.8 BCA n ¼ 2 85.3 93,4% 88.5%/12 24,4
LSA n ¼ 59 83.6%/24
RSA n ¼ 13 77.2%/60
Modarai12 2004 35 100 BCA n ¼ 1 97.5 85.4% 82.0%/48 48
LSA n ¼ 34
Gonzales13 2002 9 88.9 BCA n ¼ 2 100 100% 77.8%/40 37.4
LSA n ¼ 7
Korner14 1999 43 0 BCA n ¼ 4 100 84.0% 72.0%/100 15
LSA n ¼ 38
LSAeLSA bypass n ¼ 1
Sullivan7 1998 87 100 BCA n ¼ 7 90.3 94.3% 85.0%/35 14.3
LSA n ¼ 66
CCA n ¼ 14
Motarjeme8 1993 131 0 BCA n ¼ 9 93.0% 96.3%/60 60
LSA n ¼ 66
CCA n ¼ 6
Axillary n ¼ 3
Brachial n ¼ 3
Vertebral n ¼ 35
Internal carotid n ¼ 7
External carotid n ¼ 2
Selby15 1992 32 0 BCA n ¼ 2 81.2 100% 96.6%/90 36
LSA n ¼ 18
RSA n ¼ 8
Axillary n ¼ 4
PSR ¼ primary success rate; SR ¼ Survival rate; FU ¼ Follow-up; RSA ¼ right subclavian artery.
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AABO stenosis.
Patients with symptomatic AABO stenosis are also at
substantial risk of developing a stenosis in another AABO. In
the present series, based on a total follow-up of 163
months, the risk of new symptomatic lesions developing in
a different AABO was 2.3% per year.
This study has several limitations. The main limitation is
its retrospective nature. Consecutive case series were
collected from two large vascular referral centers, but the
caseload during this 17-year period is still limited, without
meaningful opportunity to study technical aspects of the
procedure or subgroups. However, the largest study8 pub-
lished so far reported mid-term outcome, especially
showing the risk for future symptomatic arch vessel origin
stenosis. Owing to the long period studied (September 1995
until March 2012), the population was not homogeneous.
Also, during the study period signiﬁcant technical advances
were made, biasing the results. Follow-up data weremissing for 19.0% of the patients. However, documentation
was accurate in all patients included, and all DUS reports
were accessible on the hospitals’ digital databases. Proce-
dural and in-hospital clinical outcomes were available for all
144 interventions. Because of the low incidence of this
pathology, a randomized trial of AABO therapy may be
beyond expectation.
The lack of signiﬁcant differences in secondary end point
rates in the present study between angioplasty alone and
angioplasty with additional stenting and secondary end
point rates between the different supra-aortic vessels
(Fig. 2C, D) is probably a result of the very small size of the
PTA-only group and the inherent selection bias occurring
because lesions with less tendency to recoil after PTA are
probably over-represented in this group, and these patients
are likely to perform better during follow-up.
In conclusion, the present study found that endovascular
intervention for primary atherosclerotic occlusive disease of
aortic arch branch origin stenosis is a procedure of
20 M.A.J. van de Weijer et al.acceptable safety with good mid-term results. Most pa-
tients with restenosis could be successfully treated with
renewed endovascular means. Endovascular treatment
should be the preferred treatment in AABO obstruction.
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